Hepatitis C Virus Projections Working Group / Oxford University Press / GlaxoSmithKline / Merck / Ades AE / Bristol-Myers Squibb / /
Country
Switzerland / United States / Australia / United Kingdom / Scotland / Wales / /
Currency
GBP / USD / EUR / / /
EntertainmentAwardEvent
New Investigator Award / /
Facility
University of Strathclyde / UK National Institute / Canynge Hall / National Institute / University of Bristol / Marys University of London / /
IndustryTerm
treatment of hepatitis C / online version / Prevention of Hepatitis C / hospital community health services / healthcare strategies / Health utilities / healthcare provider perspective / therapy for hepatitis C / treatment infrastructure / pharmaceutical benefits / treatment services / HCV treatment / inpatient/outpatient services / prevention of HCV / treatment for hepatitis C / healthcare providerdefined threshold / hepatitis C treatment / /
MedicalCondition
endemic infection / primary liver cancer / C hronic hepatitis C / histologically mild chronic hepatitis C. Gut / cirrhosis TP* Cirrhosis/decompensated cirrhosis / chronic prevalence / HCV chronic prevalence scenarios / Cramp M / cirrhosis / hepatitis C / hepatitis B / Utility Values Uninfected Ex/non-IDU IDU Mild HCV* Moderate HCV* Cirrhosis* Decompensated cirrhosis / cirrhosis TP* Cirrhosis / hepatitis / future liver disease / chronic HCV infection / infections / HCV genotype 2 / each baseline chronic prevalence / disease / L. Can hepatitis C / chronic prevalence scenarios / HCV chronic prevalence / hepatocellular carcinoma / chronic HCV / Gold J. Hepatitis C / De Angeles D. Hepatitis C / HCV / IDU population Infection / mild chronic hepatitis C / Onward infections / death TP* Decompensated cirrhosis / IDU infection / each disease / infection / baseline chronic prevalence settings / milder liver disease / future infections / chronic infection / HCV disease / chronic prevalence scenario / chronic hepatitis C / treating chronic HCV infection / /
Liver Unit / Department of Social Medicine / Dept of Health / National Science Foundation / London School of Hygiene and Tropical Medicine / Faculty of Public Health and Policy / London School of Medicine / National Institute for Health / Medicare / Government Actuary’s Department / National Institute for Health and Clinical Excellence / University of Bristol / University of Strathclyde / Glasgow / American Association for the Study of Liver Diseases / Oxford University / Department of Health / British Medical Association / University of London / Hope V / National Institute for Clinical Excellence / /
Person
Judd A. Modelling / Goldberg / Van Den Berg / MARTIN ET AL / Graham Foster / Williams J. Assessing / Ann Intern Med / Natasha K. Martin / Ramsay M. An / / /
Position
Investigator / editor / consultant / UK General / nurse / min nurse / multidisciplinary group model for the treatment / /
Cost-Effectiveness of Hepatitis C Virus Antiviral Treatment for Injection Drug User Populations Natasha K. Martin,1,2 Peter Vickerman,1,2 Alec Miners,2 Graham R. Foster,3 Sharon J. Hutchinson,4,5 David J. Goldberg,4 and